COMMUNIQUÉS West-GlobeNewswire

Axovant Announces Reverse Share Split Effectiveness
07/05/2019
Shares to begin trading on split-adjusted basis on May 8, 2019 BASEL, Switzerland, May 07, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene [...]
Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement
07/05/2019
No Shareholder Action Required at this Time NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted [...]
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
07/05/2019
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic [...]
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
07/05/2019
NEW YORK and CLEVELAND, May 07, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the following upcoming investor [...]
MyoKardia Announces Inaugural MyoSeeds Research Grants Program Awardees
07/05/2019
Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering [...]
TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019
07/05/2019
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and [...]
Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
07/05/2019
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated [...]
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
07/05/2019
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – [...]
Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
07/05/2019
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019 Site selection underway for Phase 2 trial of KZR-616 for the treatment of dermatomyositis [...]
New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
07/05/2019
NEURO-TTR phase 3 open-label extension study showed TEGSEDI ® ( inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy Greater efficacy [...]
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
07/05/2019
Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: [...]
Wright Medical Group N.V. Reports 2019 First Quarter Financial Results
07/05/2019
First Quarter 2019 Net Sales, Including Cartiva ® , of $230 Million, Representing As-Reported Growth of 16%, Constant Currency Growth of 18% and Organic Constant Currency Growth of 13% First Quarter 2019 Record Gross [...]
Fulgent Genetics Reports First Quarter 2019 Financial Results
07/05/2019
First Quarter 2019 Results : Revenue totals $5.4 million, growing 15% year over year Billable tests delivered total 7,530, growing 63% year over year GAAP loss of $1.9 million, or $0.10 per share Non-GAAP loss of $1.0 [...]
Aduro Biotech Reports First Quarter 2019 Financial Results
07/05/2019
BERKELEY, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and [...]
Eton Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Business Progress
07/05/2019
– Four Products Currently Under Review with the FDA – – Expecting Multiple Product Launches in Second Half of 2019 – – Company to Host Conference Call and Webcast today at 4:30 p.m. ET (3:30 p.m. CT) - DEER PARK, Ill., [...]
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
07/05/2019
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release [...]
CohBar Reports First Quarter 2019 Financial Results and Business Update
07/05/2019
Company to host conference call and webcast today, May 7, at 5:00 p.m. EDT MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria [...]
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
07/05/2019
COPENHAGEN, Denmark, May 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced [...]
Editas Medicine Announces First Quarter 2019 Results and Update
07/05/2019
- Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587) for LCA10 on track for first patient dosing [...]

Pages